Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Jesús M. Bañales(University of the Basque Country), Apinya Jusakul(Khon Kaen University), Shahid A. Khan(Imperial College London), Luca Fabris(University of Padua), Aldo J. Montaño‐Loza(University of Alberta), Jean‐Charles Nault(Assistance Publique – Hôpitaux de Paris), Mathias Heikenwälder(University of Tübingen), Anna Saborowski(Medizinische Hochschule Hannover), Guido Carpino(Sapienza University of Rome), Bas Groot Koerkamp, Benjamin Goeppert(University of Bern), Alessandro Parisi(Marche Polytechnic University), Jesper B. Andersen(University of Copenhagen), Cédric Coulouarn(Inserm), Anthony Turpin(Centre National de la Recherche Scientifique), Trine Folseraas(Oslo University Hospital), Chiara Braconi(Beatson West of Scotland Cancer Centre), Alessandra Elvevi(Azienda Ospedaliera San Gerardo), Rocı́o I.R. Macı́as(Universidad de Salamanca), María J. Perugorria(Ikerbasque), Cristina Dopazo(Universitat Autònoma de Barcelona), Ana Lleò(Humanitas University), Heinz‐Josef Klümpen(University Medical Center Groningen), Mathew Vithayathil(Hammersmith Hospital), Chiara Raggi(University of Florence), Ana Landa-Magdalena(Clinica Universidad de Navarra), Lorenza Rimassa(Humanitas University), Alejandro Forner(Hospital Clínic de Barcelona), Julien Edeline(Inserm), Paula Olaizola(University of the Basque Country), Pedro M. Rodrigues(Ikerbasque), Luke Boulter(Edinburgh Cancer Research), Patricia Aspichueta(University of the Basque Country), Juan W. Valle(Cancer Research UK Manchester Institute), Vincenzo Cardinale(Erasmus MC), Arndt Vogel(Princess Margaret Cancer Centre), Timothy J. Kendall(Edinburgh Royal Infirmary), Andrés Cárdenas(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Stacie Lindsey(Cholangiocarcinoma Foundation), Angela Lamarca(Hospital Universitario Fundación Jiménez Díaz), John Bridgewater(University College London Hospitals NHS Foundation Trust), Silvia Affò(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Diego F. Calvisi(University of Regensburg), Abel Sanchez(Universidad de San Carlos de Guatemala), Alexander Link(Friedrich-Alexander-Universität Erlangen-Nürnberg), Tom Luedde(Düsseldorf University Hospital), Anu Ustav(University of Tartu), Helen Morement(CRUK Lung Cancer Centre of Excellence)
Cited by 52
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k